News Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 01:55:00 10/06/26 am AEST			5-day change	1st Jan Change
77.04 ^EUR	+0.48%		+4.93%	-6.87%

09/06	Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial	MT
09/06	SANOFI : Deutsche Bank remains its Buy rating	ZD

All News

Mentions Relevance

09/06	SANOFI : Deutsche Bank remains its Buy rating	ZD
09/06	Sanofi Receives European Commission Approval For Sarclisa Subcutaneous As First Anticancer Treatment Administered Via On-Body Injector	CI
08/06	Sanofi's Subcutaneous Sarclisa Approved in EU Across Multiple Myeloma Indications	MT
08/06	Sanofi Wins EU Approval for Subcutaneous Sarclisa in Multiple Myeloma	MT
08/06	Brussels greenlights subcutaneous administration for Sanofi's Sarclisa
08/06	Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector	GL
05/06	Owkin And Sanofi Enter Multi-Year Collaboration To Co-Develop Next-Generation Biopharma Agents Backed By Five-Year License For K Pro	CI
05/06	Sanofi federates the healthcare ecosystem to accelerate the diagnosis of rare diseases in France, Biogen joins accelRare	AQ
04/06	Sanofi among top performers as Jefferies reiterates Buy rating
04/06	Sanofi to launch global employee share ownership plan
04/06	Sanofi launches 2026 global employee stock purchase plan	GL
04/06	SANOFI : Gets a Buy rating from Jefferies	ZD
03/06	UPC Turns Three: Statistics, Milestones, And Trends	AQ
29/05	Sanofi's Immune Thrombocytopenia Therapy Secures Regulatory Approval in UK	MT
29/05	UK's MHRA approves rilzabrutinib to treat adults with immune thrombocytopenia	RE
29/05	Sanofi's venglustat granted priority review by the FDA for treatment of GD3 (May 28)	RE
29/05	Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease	AQ
29/05	US FDA advisers vote in favor of recommending COVID vaccines target XFG variant	RE
28/05	Sanofi says manufacturing XFG protein Nuvaxovid vaccine as its single global COVID-19 product for the 2026-27 season: briefing docs	RE
28/05	SANOFI : Deutsche Bank maintains a Buy rating	ZD
28/05	Sanofi Granted FDA Priority Review for Potential Treatment of Rare Gaucher Disease	MT
28/05	The US Food and Drug Administration Accepts Sanofi?s venglustat for priority review in the US to treat type 3 Gaucher disease	CI
28/05	Sanofi granted Priority Review for Gaucher disease treatment
28/05	Sanofi's Type 3 Gaucher Treatment Secures US FDA Priority Review Status	MT
28/05	Sanofi's venglustat granted priority review by the FDA for treatment of MG3	RE